These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28640529)

  • 41. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
    Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation.
    Mjörnstedt L; Schwartz Sørensen S; von Zur Mühlen B; Jespersen B; Hansen JM; Bistrup C; Andersson H; Gustafsson B; Solbu D; Holdaas H
    Transpl Int; 2015 Jan; 28(1):42-51. PubMed ID: 25176389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
    Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK
    J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose calcineurin inhibitor-free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia.
    Hu YN; Lee NY; Roan JN; Hsu CH; Luo CY
    Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28425200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study.
    Saliba F; Duvoux C; Dharancy S; Dumortier J; Calmus Y; Gugenheim J; Kamar N; Salamé E; Neau-Cransac M; Vanlemmens C; Durand F; Pageaux GP; Hardwigsen J; Benkhatar Y; Derquenne F; Conti F
    Liver Int; 2022 Nov; 42(11):2513-2523. PubMed ID: 35962772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
    Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
    Seckinger J; Sommerer C; Hinkel UP; Hoffmann O; Zeier M; Schwenger V
    J Hypertens; 2008 Nov; 26(11):2213-9. PubMed ID: 18854763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels.
    Gustafsson F; Gude E; Sigurdardottir V; Aukrust P; Solbu D; Goetze JP; Gullestad L
    Biomark Med; 2014; 8(2):239-45. PubMed ID: 24521021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T
    Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
    Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?
    Gude E; Gullestad L; Andreassen AK
    Curr Opin Organ Transplant; 2017 Jun; 22(3):198-206. PubMed ID: 28463861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and safety of mammalian target of rapamycin inhibitors ab initio after liver transplantation without corticosteroids or induction therapy.
    Manzia TM; Angelico R; Toti L; Belardi C; Cillis A; Quaranta C; Tariciotti L; Katari R; Mogul A; Sforza D; Orlando G; Tisone G
    Dig Liver Dis; 2016 Mar; 48(3):315-20. PubMed ID: 26682720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.
    De Simone P; Fagiuoli S; Cescon M; De Carlis L; Tisone G; Volpes R; Cillo U;
    Transplantation; 2017 Feb; 101(2):239-251. PubMed ID: 27495768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
    Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
    Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.